Rosenow T, Biedendieck C, Fricke H, Brinkmann M, Cirkel U, Reinbold W-D, Fricke E
Institut für Diagnostische Radiologie, Neuroradiologie u. Nuklearmedizin, Klinikum Minden, Minden.
Klinik für Gynäkologie und Geburtshilfe, Klinikum Minden, Minden.
Geburtshilfe Frauenheilkd. 2012 Nov;72(11):1024-1028. doi: 10.1055/s-0032-1315304.
Intradermal periareolar injection technique for sentinel lymph node biopsy (SLNB) may offer an advantage by including multifocal breast cancer as an additional indication. In May 2008 we changed our standard procedure from peritumoral (PT) to periareolar (PA) injection. We compared the results for corresponding periods before and after the change in procedure. A total of 117 patients (pts.) were investigated the year after we changed our technique; a total of 152 pts were investigated in the reference period 2007. We investigated the identification rates for sentinel lymph nodes (SLN) identified scintigraphically and surgically as well as the rates of metastatic involvement (LN). After PT injection, scintigraphic detection of SLN failed in 5/152 pts., and in a further 10 pts. SLN was not found at surgery. In 7 of 15 pts. in whom SLN was not detected, histology demonstrated nodal involvement. Metastases were found in the SLN of 28 of 137 pts. with successful detection of SLN; no other lymph nodes were affected in 21 of these pts. (75.0 % of pts. with positive SLN detection). With PA injection at least one SLN could always be detected using scintigraphy; only 2/117 SLN could not be found intraoperatively. Metastasis was found in SLN in 34/115 pts.; in 19/34 pts., metastatic involvement was limited to the SLN with no other lymph nodes involved (55.9 % of pts. with positive detection of SLN). The detection rate for SLN was significantly higher using PA injection (98.3 % vs. 90.1 %). As axillary dissection was not done in SLN-negative patients, rates of false-negative detection cannot be determined. PA injection not only results in better detection rates, it also offers the advantage that the technique can be performed correctly regardless of tumour localisation.
用于前哨淋巴结活检(SLNB)的乳晕周围皮内注射技术,通过将多灶性乳腺癌作为额外适应症,可能具有一定优势。2008年5月,我们将标准操作从肿瘤周围(PT)注射改为乳晕周围(PA)注射。我们比较了操作改变前后相应时期的结果。在我们改变技术后的一年里,共对117例患者进行了研究;在2007年的参考期内共对152例患者进行了研究。我们调查了通过闪烁显像和手术确定的前哨淋巴结(SLN)的识别率以及转移累及率(LN)。PT注射后,152例患者中有5例闪烁显像未能检测到SLN,另有10例患者手术时未发现SLN。在15例未检测到SLN的患者中,有7例组织学显示有淋巴结受累。在成功检测到SLN的137例患者中,有28例在SLN中发现转移;其中21例患者(75.0%的SLN检测阳性患者)没有其他淋巴结受累。采用PA注射时,通过闪烁显像总能检测到至少一个SLN;术中仅2/117个SLN未被发现。115例患者中有34例在SLN中发现转移;在34例中的19例患者中,转移仅局限于SLN,没有其他淋巴结受累(55.9%的SLN检测阳性患者)。采用PA注射时SLN的检测率显著更高(98.3%对90.1%)。由于SLN阴性患者未进行腋窝清扫,因此无法确定假阴性检测率。PA注射不仅检测率更高,而且还具有无论肿瘤定位如何都能正确实施该技术的优势。